Revenues for the year stood at Rs 278.3 crore, 17.39 per cent lower than the Rs 326.7 crore posted in the previous year quarter, as per the consolidated results.
"The year 2007-08 has been a good year for the company and it was the first full year of operations as a pure oncology player and the focus has started yielding results," said Ajay Kumar Vij, chief executive officer of Dabur Pharma.
He said investments being done in research and international market development would ensure the growth momentum in future. The approval of indigeneously developed 'Nanoxel', a nano tech based drug eluting stent, is an example of how the company's commitment towards research is bearing fruit.
The company said overall sales were lower than the previous year mainly on account of the divesture of non-oncology business to Alembic in March, last year. However, on a like to like basis, the oncology business recorded a sales growth of over 11 per cent on a consolidated basis and 5 per cent in a standalone basis.
Though the oncology formulations business grew 30 per cent, the bulk active business saw a decrease in overall sales compared to last year on account of increased captive consumption for the formulation business.